Testing NMN for treating mild ulcerative colitis

A Single-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Trial of Nicotinamide Mononucleotide in the Treatment of Mild Ulcerative Colitis

This study is testing if a supplement called NMN can help adults with mild ulcerative colitis feel better and improve their gut health compared to a placebo.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 48 (estimated)
• Ages: 18 Years to 75 Years
• Sex: All
• Sponsor: The Third Xiangya Hospital of Central South University (other)
• Locations: 1 site (Changsha, Hunan)
• Trial ID: NCT06214078 on ClinicalTrials.gov

What this trial studies

This clinical trial aims to evaluate the safety and efficacy of nicotinamide mononucleotide (NMN) compared to a placebo in patients diagnosed with mild ulcerative colitis. Participants will be randomly assigned to receive either NMN or a placebo for a duration of 8 weeks. The primary objective is to determine if NMN can improve intestinal health and alleviate symptoms associated with ulcerative colitis. The study will involve adult patients aged 18 to 75 who meet specific inclusion criteria.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18 to 75 with a clinical diagnosis of mild active ulcerative colitis.

Not a fit: Patients with severe liver dysfunction, chronic intestinal infections, or other specified exclusion criteria may not benefit from this study.

Why it matters

Potential benefit: If successful, this intervention could provide a new treatment option for patients with mild ulcerative colitis.

How similar studies have performed: While NMN has been studied for various health benefits, this specific application in mild ulcerative colitis is novel and has not been extensively tested in prior studies.

Eligibility criteria

Inclusion Criteria:

1. Age ≥18 years old, ≤75 years old;
2. Clinical diagnosis of mild active UC patients, the diagnosis standard reference inflammatory bowel disease diagnosis and treatment of the consensus of opinion 2018.
3. Agreed to participate in this study, and sign the informed consent.

Exclusion Criteria:

1. Patients with ALT or AST more than 2 times the upper limit of normal, TBIL more than 2 times the upper limit of normal;
2. The creatinine clearance patients less than 60 ml/min.
3. The intestines or other parts have severely active infection patients need to use antibiotics or antiviral drugs;
4. Crohn's disease and intestinal tuberculosis and other chronic intestinal infectious disease, intestinal malignant tumor patients;
5. Pregnancy and lactation women;
6. People with diabetes or screening period more than 7.0 tendency for fasting glucose/L or glycosylated hemoglobin exceed 6.5%;
7. With serious mental illness, such as drugs and alcohol can't cooperate with the patients;
8. Participated in any other clinical investigator within 1 month before the screening period;
9. The researchers determine any other disease or condition is not suitable for patients participate in the study.

Where this trial is running

Changsha, Hunan

• The Third Xiangya Hospital of Central South University — Changsha, Hunan, China (RECRUITING)

Study contacts

• Principal investigator: Xiaoyan Wang — The Third Xiangya Hospital of Central South University
• Study coordinator: Xiaoyan Wang

Conditions: Ulcerative Colitis Chronic Mild